California Public Employees Retirement System Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

California Public Employees Retirement System lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,914 shares of the medical research company's stock after selling 8,183 shares during the quarter. California Public Employees Retirement System owned 0.17% of Charles River Laboratories International worth $15,675,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Versant Capital Management Inc boosted its stake in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after buying an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. grew its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the period. Tortoise Investment Management LLC increased its stake in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after purchasing an additional 115 shares during the last quarter. ORG Wealth Partners LLC bought a new position in Charles River Laboratories International during the fourth quarter worth about $56,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the third quarter valued at approximately $59,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Remove Ads

Insider Buying and Selling at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was purchased at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Mizuho decreased their price objective on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Finally, Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and an average price target of $183.62.

Charles River Laboratories International Price Performance

CRL stock traded up $15.30 during trading on Wednesday, reaching $138.91. 1,974,887 shares of the company were exchanged, compared to its average volume of 787,432. The company has a 50-day moving average of $159.23 and a two-hundred day moving average of $178.36. The company has a market capitalization of $6.82 billion, a price-to-earnings ratio of 926.07, a P/E/G ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a twelve month low of $117.26 and a twelve month high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $983.63 million. During the same period in the prior year, the company posted $2.46 EPS. The company's revenue was down 1.1% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).